Induced sputum differential cell counts have been advocated as a method of non-invasively assessing airway inflammation in asthma and other airway diseases. Since sputum induction usually involves delivering hypertonic saline via a high output ultrasonic nebulizer there have been concerns about its safety in asthma. There are relatively little data on the effects of sputum induction in large numbers of patients. We have examined the success rate and effect of sputum induction on forced expiratory volume in 1 set (FEV,) in 100 inductions performed on 79 patients using a low output nebulizer. Thirty-seven patients had asthma, 29 had miscellaneous conditions (mainly chronic cough) and 13 were subjects without respiratory symptoms. Sputum was induced 10 min after 200,~g of inhaled salbutamol by sequential 5-min inhalations of 3, 4 and 5% saline delivered via a Fisoneb ultrasonic nebulizer and FEV, was measured after each inhalation. Sputum induction resulted in a sample suitable for analysis in 92% of asthmatics, 90% of those with miscellaneous conditions and 100% of normal subjects. The mean (SEM) maximum per cent fall in FEV, was 5.4% (0. l), 4.3% (1 .O) and 2.6% (1.1) in subjects with asthma, miscellaneous conditions and in asymptomatic subjects respectively. Only 13 inductions resulted in a >lO% fall in FEV,, and only three of these resulted in a >20% fall. The maximum per cent fall in FEV, did not correlate with baseline FEV, % predicted (Y= -0.17), the log sputum eosinophil count (u= -@12), or the methacholine PC,, (r= -0 14). We conclude that sputum induction using a relatively low output ultrasonic nebulizer with premeditation with salbutamol is successful and safe in the majority of patients with asthma and other airway conditions.
Introduction
Sputum induction as a non-invasive method of investigating lower airways inflammation in asthma was first suggested by Pin et al. in 1992 (1) . Since then a number of different methods for induction have been advocated. The different protocols vary in the output of the nebulizer, duration of nebulization and the concentration of saline used (l-3). Relatively little is known about the safety of these protocols in subjects with asthma.
Hypertonic saline has previously been used in bronchoprovocation tests, so there have been concerns about its safety in subjects with asthma (4) . We have examined the effect of sputum induction using a low output ultrasonic nebulizer in 100 consecutive inductions performed on 79 subjects. We have compared the effect of sputum induction on forced expiratory volume in 1 set (FEV,) in subjects with asthma, miscellaneous airway conditions and in subjects with no respiratory symptoms and have investigated whether the change in FEV, was related to the baseline FEV, % predicted, methacholine airways responsiveness or sputum eosinophil count.
Methods

SUBJECTS
One hundred consecutive inductions were performed on 79 patients and volunteers referred from general respiratory clinics. Thirty-seven patients had a diagnosis of asthma, 29 patients had miscellaneous airways conditions (12 with cough of unknown cause, seven with eosinophilic bronchitis, four with sarcoidosis and six with other miscellaneous respiratory conditions) and 13 subjects had no history of asthma or other respiratory symptoms and a methacholine PC,, of greater than 8 mg ml -i. Asthma was diagnosed in subjects with consistent symptoms and one or more of the following: a > 15% increase in FEV, 10 min after 2OOpg inhaled salbutamol, maximum within day peak expiratory flow variability of >20% or a methacholine PC,, <8mgml-i. Eleven asthmatic subject and six normal subjects had two inductions; one asthmatic had three inductions; and one had four inductions. Subjects' details A successful induction was considered to be one that produced sputum that was suitable for analysis.
MEASUREMENTS STATISTICS
Bronchoprovocation testing was performed using the tidal breathing method as previously described (5). Sputum was induced using a modified version of the technique described by Pin et al. (1, 6) . Subjects' FEV, was measured using a micro-plus spirometer (Micromedical, Gillingham, U.K.), before and 10 min after treatment with 2OOpg of salbutamol inhaled via a volumatic. Induction was then performed using 5 ml of 3% saline nebulized via a Fisoneb (Clement Clark, Harlow, U.K.) ultrasonic nebulizer (output 0.9 ml min -i, mean mass diameter 5.6pm) for 5 min. FEV, was then remeasured; the subject was then asked to blow their nose and rinse their mouth and cough into a sterile container. If the fall in FEV, was less than 10% compared to the post-bronchodilator FEV, the induction was repeated using 4% followed by 5% saline. If the FEV, fall was between 10 and 20% the previous concentration of saline was used, if the fall was greater than 20% then the procedure was discontinued.
Data are presented as mean and standard error of the mean (SEM).
The baseline FEV, was defined as the postsalbutamol reading and both the FEV, % predicted and the percentage fall in FEV, were calculated in relation to this. Methacholine PC,, and sputum differential eosinophil counts were log-transformed to give a normal distribution and described as the geometric mean. The change in FEV, after each concentration was expressed as percentage change from baseline (post-salbutamol) and the maximum fall in FEV, was defined as maximum decrease observed after any concentration of hypertonic saline. The change in FEV, after each concentration and the maximum percentage fall in FEV, were compared between groups by oneway ANOVA. If no fall was observed it was assigned as no change. The maximum fall in FEV, was correlated with the log eosinophil count, the log methacholine PC,, and FEV, % predicted using Pearson's correlation coefficient.
Sputum was processed as has been previously described (6) . Briefly sputum was selected from saliva, weighed and dispersed using four volumes 0.1% dithiothreitol. After 15 min gentle rocking the cell suspension was diluted with a further four volumes of Dulbecco's phosphate-buffered saline and filtered through a 48 pg nylon gauze. Squamous cell count and total cell count were obtained using a Neubauer haemocytometer and cell viability was assessed by the trypan blue exclusion method. The cell suspension was adjusted to 0.75 x lo6 cells ml -' and 75 ~1 cell suspension was used to prepare cytospins at 450 rpm for 6 min
Results
Sputum induction was successful (as defined above) in 92% of patients with asthma, 90% of patients with miscellaneous conditions and 100% of normal subjects. The mean (SEM) maximum fall in FEV, was 5.4% (0.1) in asthmatics, 4.3% (1.0) in those with miscellaneous conditions and 2.6% (1.1) in the normal subjects (P>O.O5; Table 1 ). Thirteen inductions (nine on subjects with a diagnosis of asthma, three on subjects with a miscellaneous diagnosis and one on a control subject) resulted in a greater than 10% fall in FEV,. Six developed the fall after 3% saline, four after 4% saline and three after 5% saline. Three patients (all with asthma) had a greater than 20% fall in their FEV, (maximum 23%). One developed the fall in FEV, after 4% saline, the other two after 5% saline. Five subjects with a greater than 10% fall had repeat inductions which resulted in three of these subjects again dropping their baseline FEV, by greater than 10%. All subjects recovered promptly to within 5% of their baseline FEV, 10 minutes after a further 200 pg of inhaled salbutamol and there were no long-term sequelae. The mean change in FEV, in each group with each concentration of saline did not differ significantly between the groups (P>O.O5; Table 2 ). There was no correlation between the maximal fall in FEV, and either FEV, % predicted (r= -0.17) the log sputum eosinophil count (r= -0.12) or the log PC,, (r= -0 14).
Discussion
We have shown that, after pretreatment with salbutamol, sputum induction using a low output nebulizer is both safe and successful. Our success rates are higher than those reported in smaller studies using essentially the same sputum induction protocols (1) . This may reflect a lower threshold for accepting sputum as suitable for analysis or the fact that we carried out sputum induction irrespective of whether the subject could produce sputum spontaneously, while others (1) have restricted the technique to subjects unable to spontaneously produce sputum.
Two further large studies (7,s) have addressed the issue of safety of sputum induction using hypertonic saline. Both of these used slightly different induction protocols to ourselves. Wong et al. (7) administered 3% saline via a relatively high output nebulizer (output 2.4 ml min -') and did not measure the FEV, until the end of the 20-min induction, whereas de la Fuente et al. (8) used a similar protocol to ourselves with increasing concentrations of hypertonic saline, but again used a relatively high output nebulizer (output 2.4 ml min-'). Wong et al. reported a higher incidence of severe bronchoconstriction and a slightly greater mean maximum fall in FEV, in subjects with asthma (7) while de la Fuente et al. reported a similar mean maximal fall in FEV, but a slightly higher proportion of subjects with a greater than 10% fall in FEV,. Bronchoconstriction in response to inhaled hypertonic saline in subjects with asthma is related to the total dose delivered and the rate of delivery (4) so reduced nebulization times and (in our case) a low output of the nebulizer would be expected to cause less bronchoconstriction. Furthermore, our more frequent monitoring of FEV, during, the procedure may result in recognition of bronchoconstriction before it becomes severe since subjects with asthma typically develop a fall in their FEV, during the first 15 ml of nebulized hypertonic saline (4). It is notable that Wong and colleagues have now recommended similar more frequent monitoring (7) . Our use of a low output nebulizer did not result in a lower success rate than that of de la Fuente et al. or other protocols using high output nebulizers (2,3) suggesting that these more aggressive induction protocols do not have any particular advantage. Such techniques may also have the disadvantage of causing neutrophilic airway inflammation (9,lO) .
The safety of sputum induction would be increased if it were possible to identify subject characteristics that predicted a bronchoconstrictor response to hypertonic saline. We were unable to find a relationship between change in FEV, in response to hypertonic saline and either the baseline FEV,, the sputum eosinophil count or the methacholine airway responsiveness. This may be because the effect of hypertonic saline was so small in our study. Wong et al. (7) found a more clear-cut relationship between change in FEV, and all three features of asthma, perhaps because the between subject variability in the response to hypertonic saline was more marked and the subjects had a wider range of baseline airway responsiveness.
As with most other studies, our subjects with asthma had relatively mild stable disease and this might have limited the effect of nebulized hypertonic saline. In support of this Pizzichini et al. (11) have recently shown that sputum induction using a low output ultrasonic nebulizer in unstable asthma is associated with a >20% fall in FEV, in up to one-third of patients despite salbutamol premeditation and the use of reduced volumes and concentrations of hypertonic saline. There was no clear association with a low baseline FEV, and high sputum eosinophil count, although the risk appeared to be highest in subjects using frequent and high doses of inhaled &agonists over the preceding 24 h. De la Fuente et al. (8) also found a higher incidence of severe adverse events in the severe asthmatics (FEV, < 1 litre) during their preliminary study and in fact excluded these subjects from the full study. These findings emphasize the importance of careful monitoring of patients with unstable asthma during sputum induction.
In conclusion, we have shown that, with salbutamol premeditation and careful monitoring of FEV, in clinically stable patients, sputum induction is safe and that using a low output nebulizer has no detrimental effect on the success rate. In this clinical setting we were unable to identify any particular subject characteristics associated with an increased risk of significant bronchospasm.
